231 related articles for article (PubMed ID: 27014780)
1. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.
Khawaja MR; Nick AM; Madhusudanannair V; Fu S; Hong D; McQuinn LM; Ng CS; Piha-Paul SA; Janku F; Subbiah V; Tsimberidou A; Karp D; Meric-Bernstam F; Lu KH; Naing A
Cancer Chemother Pharmacol; 2016 May; 77(5):973-7. PubMed ID: 27014780
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of temsirolimus and metformin in advanced solid tumours.
MacKenzie MJ; Ernst S; Johnson C; Winquist E
Invest New Drugs; 2012 Apr; 30(2):647-52. PubMed ID: 20978924
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies.
Trivedi ND; Armstrong S; Wang H; Hartley M; Deeken J; Ruth He A; Subramaniam D; Melville H; Albanese C; Marshall JL; Hwang J; Pishvaian MJ
Cancer Med; 2021 Mar; 10(6):1944-1954. PubMed ID: 33638305
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.
Kyriakopoulos CE; Braden AM; Kolesar JM; Eickhoff JC; Bailey HH; Heideman J; Liu G; Wisinski KB
Invest New Drugs; 2017 Jun; 35(3):290-297. PubMed ID: 28004284
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer.
Ganesan P; Piha-Paul S; Naing A; Falchook G; Wheler J; Janku F; Zinner R; Laday S; Kies M; Tsimberidou AM
Invest New Drugs; 2013 Dec; 31(6):1505-13. PubMed ID: 23982248
[TBL] [Abstract][Full Text] [Related]
7. Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors.
Amin M; Gao F; Terrero G; Picus J; Wang-Gillam A; Suresh R; Ma C; Tan B; Baggstrom M; Naughton MJ; Trull L; Belanger S; Fracasso PM; Lockhart AC
Am J Clin Oncol; 2021 Sep; 44(9):443-448. PubMed ID: 34310349
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.
Mita M; Fu S; Piha-Paul SA; Janku F; Mita A; Natale R; Guo W; Zhao C; Kurzrock R; Naing A
Invest New Drugs; 2017 Oct; 35(5):616-626. PubMed ID: 28194539
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM
BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.
Becher OJ; Gilheeney SW; Khakoo Y; Lyden DC; Haque S; De Braganca KC; Kolesar JM; Huse JT; Modak S; Wexler LH; Kramer K; Spasojevic I; Dunkel IJ
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035748
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.
Spunt SL; Grupp SA; Vik TA; Santana VM; Greenblatt DJ; Clancy J; Berkenblit A; Krygowski M; Ananthakrishnan R; Boni JP; Gilbertson RJ
J Clin Oncol; 2011 Jul; 29(21):2933-40. PubMed ID: 21690471
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors.
Piatek CI; Raja GL; Ji L; Gitlitz BJ; Dorff TB; Quinn DI; Hu J; El-Khoueiry AB; Pham HQ; Roman L; Garcia AA
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1227-34. PubMed ID: 25374407
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors.
Park H; Williams K; Trikalinos NA; Larson S; Tan B; Waqar S; Suresh R; Morgensztern D; Van Tine BA; Govindan R; Luo J; Lockhart AC; Wang-Gillam A
Cancer Chemother Pharmacol; 2021 Mar; 87(3):337-347. PubMed ID: 33159216
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.
Naing A; Kurzrock R; Burger A; Gupta S; Lei X; Busaidy N; Hong D; Chen HX; Doyle LA; Heilbrun LK; Rohren E; Ng C; Chandhasin C; LoRusso P
Clin Cancer Res; 2011 Sep; 17(18):6052-60. PubMed ID: 21750201
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors.
Semrad TJ; Eddings C; Dutia MP; Christensen S; Lara PN
Anticancer Drugs; 2013 Jul; 24(6):636-40. PubMed ID: 23698253
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors.
Fury MG; Sherman E; Haque S; Korte S; Lisa D; Shen R; Wu N; Pfister D
Cancer Chemother Pharmacol; 2012 Mar; 69(3):591-8. PubMed ID: 21913034
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
Motzer RJ; Hudes GR; Curti BD; McDermott DF; Escudier BJ; Negrier S; Duclos B; Moore L; O'Toole T; Boni JP; Dutcher JP
J Clin Oncol; 2007 Sep; 25(25):3958-64. PubMed ID: 17761980
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.
Gandhi L; Bahleda R; Tolaney SM; Kwak EL; Cleary JM; Pandya SS; Hollebecque A; Abbas R; Ananthakrishnan R; Berkenblit A; Krygowski M; Liang Y; Turnbull KW; Shapiro GI; Soria JC
J Clin Oncol; 2014 Jan; 32(2):68-75. PubMed ID: 24323026
[TBL] [Abstract][Full Text] [Related]
19. A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report.
Fouladi M; Perentesis JP; Wagner LM; Vinks AA; Reid JM; Ahern C; Thomas G; Mercer CA; Krueger DA; Houghton PJ; Doyle LA; Chen H; Weigel B; Blaney SM
Clin Cancer Res; 2015 Apr; 21(7):1558-65. PubMed ID: 25467181
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies.
Temkin SM; Yamada SD; Fleming GF
Gynecol Oncol; 2010 Jun; 117(3):473-6. PubMed ID: 20347480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
